Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Jiebiao is a Traditional Chinese Medicine (TCM) oral liquid formulation primarily used in pediatric patients for the treatment of acute upper respiratory infections, influenza, and hand, foot, and mouth disease (HFMD). Developed and manufactured by companies such as ApicHope Pharmaceutical Group (Guangzhou Yipinhong), it is designed to "relieve the exterior" (Jiebiao) and clear heat, addressing symptoms like fever, cough, and sore throat. Clinical studies have evaluated its efficacy as a standalone treatment or in combination with antivirals like ribavirin or oseltamivir. The formulation typically consists of a multi-herb mixture including ingredients such as Lonicera japonica, Forsythia suspensa, and Pueraria lobata, which are traditionally used for their antipyretic and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Jiebiao.